Page 43 - Recursion Pharmaceuticals News Today

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $7.80, but opened at $7.61. Recursion Pharmaceuticals shares last traded at $7.65, with a volume of 1,456 shares. A number of equities analysts recently issued reports on RXRX shares. SVB Leerink downgraded […]

AI platforms are enhancing discovery efforts across modalities—small-molecule drugs, RNA-based therapeutics, and protein-based therapeutics.

For all the excitement around places like Austin and Miami, the biggest tech expansion has been in Canada’s largest city.

Toronto, the quietly booming tech town

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) reached a new 52-week low on Friday . The company traded as low as $8.84 and last traded at $8.85, with a volume of 6427 shares traded. The stock had previously closed at $9.70. RXRX has been the topic of a number of recent analyst reports. […]

BALTIMORE, Md. (PRWEB) March 02, 2022 -- BALTIMORE, Md. – 2 MARCH 2022 – Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit

BALTIMORE, Md. (PRWEB) March 02, 2022 -- BALTIMORE, Md. – 2 MARCH 2022 – Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital.

The Eccles School has a strong tradition of entrepreneurial education, which the new Founders Fund is meant to support and expand. 

GM2 Gangliosidoses – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030